Susquehanna Fundamental Investments’s Enanta Pharmaceuticals ENTA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,434	Closed	-$795K	–	543
2025 Q4	$795K	Hold	50,434	–	–	0.03%	372
2025 Q3	$604K	Hold	50,434	–	–	0.02%	413
2025 Q2	$381K	Sell	50,434 -42,955	-46%	-$258K	0.01%	587
2025 Q1	$516K	Buy	93,389 +75,043	+409%	+$464K	0.01%	833
2024 Q4	$105K	Buy	+18,346	New	+$176K	﹤0.01%	1039
2022 Q4	–	Sell	-6,291	Closed	-$326K	–	1277
2022 Q3	$326K	Buy	+6,291	New	+$368K	0.01%	1133
2022 Q1	$527K	Buy	7,399 +620	+9%	+$40.3K	0.01%	1061
2021 Q4	$507K	Buy	6,779 +2,610	+63%	+$205K	0.01%	910
2021 Q3	$237K	Sell	4,169 -4,495	-52%	-$222K	﹤0.01%	1484
2021 Q2	$381K	Buy	8,664 +2,652	+44%	+$130K	0.01%	1273
2021 Q1	$297K	Buy	+6,012	New	+$300K	0.01%	1294
2020 Q4	–	Sell	-16,698	Closed	-$764K	–	1528
2020 Q3	$764K	Sell	16,698 -5,218	-24%	-$253K	0.02%	735
2020 Q2	$1.1M	Buy	+21,916	New	+$1.13M	0.05%	428

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna Fundamental Investments's ENTA Position: Q1 2026 in Review

Susquehanna Fundamental Investments sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 50,434 shares — an estimated $795K sold.

Susquehanna Fundamental Investments first reported a position in ENTA in Q2 2020 and held it in 13 quarters. The position peaked at $1.1M in Q2 2020. 133 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Susquehanna Fundamental Investments reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Susquehanna Fundamental Investments sold 50,434 Enanta Pharmaceuticals shares in Q1 2026, an estimated $795K.
Susquehanna Fundamental Investments first reported a position in Enanta Pharmaceuticals in Q2 2020 and held it in 13 quarters.
Susquehanna Fundamental Investments's Enanta Pharmaceuticals position peaked at $1.1M in Q2 2020.
133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2026, filed 15 May 2026.